Büşra Topuz Türkcan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Büşra Topuz Türkcan has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Zühre Kaya
Gazi University Faculty of Medicine, Department of Pediatric Hematology, Ankara, Türkiye
2 shared publications - Özge Vural
Gazi University
2 shared publications - Ülker Koçak
Gazi University Ankara
2 shared publications - Ahmet Bayramlı
Gazi University Faculty of Medicine, Department of Pediatric Hematology, Ankara, Türkiye
1 shared publication - Arzu Okur
Gazi University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Ankara, Türkiye
1 shared publication - Aynur Oğuz
Gazi University
1 shared publication
Latest Publications
- 22 July 2026
- Published by Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Dergisi in Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi
- Vol. 21 (2) , 131-134
Effective Treatment of Pediatric Tongue Lymphangiomatosis with Sirolimus: A Case Report
Lymphangiomatosis, a rare condition characterized by the widespread development of lymphangiomas, often affects children under five years of age. Lymphangiomas, a type of lymphatic malformation, frequently manifest as cysts or lobulated masses in the head, neck, extremities, and trunk. While treatment options include observation, sclerotherapy, radiofrequency ablation, laser therapy, and surgery, the effectiveness can be limited. A 5-year-old girl was admitted to our department with a history of tongue enlargement, foul breath, bleeding, difficulty chewing, and impaired speech and nutrition. Upon physical examination, her tongue was noticeably enlarged, bluish in color, and covered with microvesicles and dark scabs. A diagnosis of microcystic lymphangioma of the tongue was confirmed through magnetic resonance imaging. Due to the inoperability of the lesion, propranolol 2 mg/kg/day was ordered for 3 months. But no improvement was seen. The patient was treated with sirolimus at a dosage of 1.8 mg/m²/day for six months. This treatment led to a noticeable reduction in lesion size. Subsequent follow-up visits, conducted every three months, revealed a significant improvement in all symptoms within one year. Treatment options for children with tongue lymphangioma are quite limited. Our findings demonstrate that sirolimus is a promising treatment option for this condition, with manageable side effects. We therefore advocate for prompt and efficient care and treatment with sirolimus in pediatric lymphangiomatosis to improve patient outcomes.
- 22 July 2026
- Published by Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Dergisi in Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi
- Vol. 21 (2) , 131-134
Effective Treatment of Pediatric Tongue Lymphangiomatosis with Sirolimus: A Case Report
Lymphangiomatosis, a rare condition characterized by the widespread development of lymphangiomas, often affects children under five years of age. Lymphangiomas, a type of lymphatic malformation, frequently manifest as cysts or lobulated masses in the head, neck, extremities, and trunk. While treatment options include observation, sclerotherapy, radiofrequency ablation, laser therapy, and surgery, the effectiveness can be limited. A 5-year-old girl was admitted to our department with a history of tongue enlargement, foul breath, bleeding, difficulty chewing, and impaired speech and nutrition. Upon physical examination, her tongue was noticeably enlarged, bluish in color, and covered with microvesicles and dark scabs. A diagnosis of microcystic lymphangioma of the tongue was confirmed through magnetic resonance imaging. Due to the inoperability of the lesion, propranolol 2 mg/kg/day was ordered for 3 months. But no improvement was seen. The patient was treated with sirolimus at a dosage of 1.8 mg/m²/day for six months. This treatment led to a noticeable reduction in lesion size. Subsequent follow-up visits, conducted every three months, revealed a significant improvement in all symptoms within one year. Treatment options for children with tongue lymphangioma are quite limited. Our findings demonstrate that sirolimus is a promising treatment option for this condition, with manageable side effects. We therefore advocate for prompt and efficient care and treatment with sirolimus in pediatric lymphangiomatosis to improve patient outcomes.
- Open Access
- 2 February 2026
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 61 (2) , 128-138
Evaluation of Retinal Toxicity in Pediatric Oncology Patients Receiving Platinum-Based Chemotherapy
Objective: Improved survival among pediatric oncology patients has increased the burden of late treatment-related complications, including retinal toxicity, a recognized acute and chronic effect of platinum chemotherapy. This study aimed to characterize retinal toxicity associated with platinum agents and compare the toxicities of cisplatin and carboplatin. Materials and Methods: Thirty-six pediatric patients (22 girls, 14 boys) who had completed platinum-based chemotherapy and were in remission were evaluated. Patients with pretreatment ocular disease or impaired renal function were excluded. Oncologic data and ophthalmologic findings including visual acuity, refractive errors, color vision, optical coherence tomography (OCT) (retinal nerve fiber layer thickness [RNFLT]; central foveal retinal thickness [CFRT]), and optical coherence tomography angiography (OCTA) (superficial capillary plexus [SCP]; deep capillary plexus [DCP]) vessel density were obtained retrospectively from medical records. Thirty-six age- and sex-matched healthy children without ocular or systemic disease served as controls. Results: Seventy eyes from the patient group and 72 from controls were analyzed. Time since last chemotherapy was negatively correlated with left-eye CFRT. Higher cumulative cisplatin dose was associated with reduced CFRT and thinning of RNFLT in the nasal-superior quadrant, while carboplatin dose showed no significant effect. Conclusion: Obvious retinal toxicity does not occur with platinum chemotherapy within the dos age range the patients received. The decrease in CFRT and RNFLT with a higher dose of cisplatin suggested that cisplatin may cause more retinal toxicity than carboplatin. The negative correlation between CFRT and duration since last chemotherapy suggests that RNFLT might get thinner over time; therefore, these patients need lifelong ophthalmologic follow-up.
- 2 February 2026
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 61 (2) , 128-138
Open AccessEvaluation of Retinal Toxicity in Pediatric Oncology Patients Receiving Platinum-Based Chemotherapy
Objective: Improved survival among pediatric oncology patients has increased the burden of late treatment-related complications, including retinal toxicity, a recognized acute and chronic effect of platinum chemotherapy. This study aimed to characterize retinal toxicity associated with platinum agents and compare the toxicities of cisplatin and carboplatin. Materials and Methods: Thirty-six pediatric patients (22 girls, 14 boys) who had completed platinum-based chemotherapy and were in remission were evaluated. Patients with pretreatment ocular disease or impaired renal function were excluded. Oncologic data and ophthalmologic findings including visual acuity, refractive errors, color vision, optical coherence tomography (OCT) (retinal nerve fiber layer thickness [RNFLT]; central foveal retinal thickness [CFRT]), and optical coherence tomography angiography (OCTA) (superficial capillary plexus [SCP]; deep capillary plexus [DCP]) vessel density were obtained retrospectively from medical records. Thirty-six age- and sex-matched healthy children without ocular or systemic disease served as controls. Results: Seventy eyes from the patient group and 72 from controls were analyzed. Time since last chemotherapy was negatively correlated with left-eye CFRT. Higher cumulative cisplatin dose was associated with reduced CFRT and thinning of RNFLT in the nasal-superior quadrant, while carboplatin dose showed no significant effect. Conclusion: Obvious retinal toxicity does not occur with platinum chemotherapy within the dos age range the patients received. The decrease in CFRT and RNFLT with a higher dose of cisplatin suggested that cisplatin may cause more retinal toxicity than carboplatin. The negative correlation between CFRT and duration since last chemotherapy suggests that RNFLT might get thinner over time; therefore, these patients need lifelong ophthalmologic follow-up.
- Open Access
- 13 January 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (2) , 233-234
Positron Emission Tomography Imaging and HScore-Based Diagnosis in Two Children with Malignancy-Associated Hemophagocytic Syndrome: Anaplastic Large-Cell Lymphoma and Precursor B-acute Lymphoblastic Leukemia
Cite this article as: Kaya Z, Kirkiz Kayalı S, Topuz Türkcan B, et al. Positron emission tomography imaging and HScore-based diagnosis in two children with malignancy-associated hemophagocytic syndrome: anaplastic large-cell lymphoma and precursor B-acute lymphoblastic leukemia. Turk Arch Pediatr. 2025;60(2):233-234.
- 13 January 2025
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 60 (2) , 233-234
Open AccessPositron Emission Tomography Imaging and HScore-Based Diagnosis in Two Children with Malignancy-Associated Hemophagocytic Syndrome: Anaplastic Large-Cell Lymphoma and Precursor B-acute Lymphoblastic Leukemia
Cite this article as: Kaya Z, Kirkiz Kayalı S, Topuz Türkcan B, et al. Positron emission tomography imaging and HScore-based diagnosis in two children with malignancy-associated hemophagocytic syndrome: anaplastic large-cell lymphoma and precursor B-acute lymphoblastic leukemia. Turk Arch Pediatr. 2025;60(2):233-234.
- Open Access
- 30 November 2022
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 39 (4) , 266-267
Methotrexate-Mediated Arachnoiditis in a Child with Acute Lymphoblastic Leukemia
- 30 November 2022
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 39 (4) , 266-267
Open AccessMethotrexate-Mediated Arachnoiditis in a Child with Acute Lymphoblastic Leukemia